Uromodulin in sepsis and severe pneumonia: a two-sample Mendelian randomization study

Area of Science:

• Nephrology
• Critical Care Medicine
• Genetics

Background:

• Sepsis-associated acute kidney injury (AKI) in intensive care units (ICUs) leads to poor patient outcomes.
• Low serum uromodulin (sUMOD) levels have been hypothesized as a mediator of this negative effect.
• Investigating the protective role of sUMOD in severe infections is crucial for understanding AKI's impact.

Approach:

• A two-sample Mendelian randomization (MR) study utilized single-nucleotide polymorphisms (SNPs) associated with sUMOD levels as instrumental variables.
• Data from six datasets across two biobanks, encompassing various cohorts, were analyzed.
• Meta-analysis combined data based on disease severity (hospital- vs. ICU-admitted) to assess associations with sepsis and pneumonia risk and mortality.

Key Points:

• No significant protective effect of increased sUMOD levels was observed on the risk of sepsis or severe pneumonia.
• Higher sUMOD levels did not reduce the risk of ICU admission for sepsis or pneumonia, nor ICU mortality in these conditions.
• Results remained consistent across different geographic origins and were not modified by disease severity.

Conclusions:

• The study found no evidence supporting a protective role for elevated serum uromodulin in sepsis or severe pneumonia.
• Findings challenge the hypothesis that sUMOD acts as a protective mediator in severe infections complicated by AKI.
• Further research may be needed to elucidate the complex relationship between kidney function markers and infection outcomes.